HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Personnel, Policy, Procedures and Follow-Up. A report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA)

Hugh Calkins; Josep Brugada; Douglas L. Packer; Riccardo Cappato; Shih Ann Chen; Harry J G Crijns; Ralph J. Damiano; D. Wyn Davies; David E. Haines; Michel Haissaguerre; Yoshito Iesaka; Warren Jackman; Pierre Jais; Hans Kottkamp; Karl Heinz Kuck; Bruce D. Lindsay; Francis E. Marchlinski; Patrick M. McCarthy; J. Lluis Mont; Fred Morady; Koonlawee Nademanee; Andrea Natale; Carlo Pappone; Eric Prystowsky; Antonio Raviele; Jeremy N. Ruskin; Richard J. Shemin

doi:10.1016/j.hrthm.2007.04.005

HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Personnel, Policy, Procedures and Follow-Up. A report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA)

Hugh Calkins, Josep Brugada, Douglas L. Packer, Riccardo Cappato, Shih Ann Chen, Harry J G Crijns, Ralph J. Damiano, D. Wyn Davies, David E. Haines, Michel Haissaguerre, Yoshito Iesaka, Warren Jackman, Pierre Jais, Hans Kottkamp, Karl Heinz Kuck, Bruce D. Lindsay, Francis E. Marchlinski, Patrick M. McCarthy, J. Lluis Mont, Fred MoradyKoonlawee Nademanee, Andrea Natale, Carlo Pappone, Eric Prystowsky, Antonio Raviele, Jeremy N. Ruskin, Richard J. Shemin

Surgery, Cardiac Surgery Division

Research output: Contribution to journal › Article › peer-review

1120 Scopus citations

Original language	English (US)
Pages (from-to)	816-861
Number of pages	46
Journal	Heart rhythm
Volume	4
Issue number	6
DOIs	https://doi.org/10.1016/j.hrthm.2007.04.005
State	Published - Jun 2007

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine
Physiology (medical)

Access to Document

10.1016/j.hrthm.2007.04.005

Cite this

Calkins, H., Brugada, J., Packer, D. L., Cappato, R., Chen, S. A., Crijns, H. J. G., Damiano, R. J., Davies, D. W., Haines, D. E., Haissaguerre, M., Iesaka, Y., Jackman, W., Jais, P., Kottkamp, H., Kuck, K. H., Lindsay, B. D., Marchlinski, F. E., McCarthy, P. M., Mont, J. L., ... Shemin, R. J. (2007). HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Personnel, Policy, Procedures and Follow-Up. A report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA). Heart rhythm, 4(6), 816-861. https://doi.org/10.1016/j.hrthm.2007.04.005

Calkins, Hugh ; Brugada, Josep ; Packer, Douglas L. et al. / HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation : Recommendations for Personnel, Policy, Procedures and Follow-Up. A report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA). In: Heart rhythm. 2007 ; Vol. 4, No. 6. pp. 816-861.

@article{694b284909dd474c95f99990532ee359,

title = "HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Personnel, Policy, Procedures and Follow-Up. A report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA)",

author = "Hugh Calkins and Josep Brugada and Packer, {Douglas L.} and Riccardo Cappato and Chen, {Shih Ann} and Crijns, {Harry J G} and Damiano, {Ralph J.} and Davies, {D. Wyn} and Haines, {David E.} and Michel Haissaguerre and Yoshito Iesaka and Warren Jackman and Pierre Jais and Hans Kottkamp and Kuck, {Karl Heinz} and Lindsay, {Bruce D.} and Marchlinski, {Francis E.} and McCarthy, {Patrick M.} and Mont, {J. Lluis} and Fred Morady and Koonlawee Nademanee and Andrea Natale and Carlo Pappone and Eric Prystowsky and Antonio Raviele and Ruskin, {Jeremy N.} and Shemin, {Richard J.}",

note = "Funding Information: Author Disclosures Task Force Members Research Grants Fellowship Support Speakers{\textquoteright} Bureau/Honoraria Ownership Interest Consultant/Advisory Board Other Josep Brugada, MD None Boston Scientific Boston Scientific Medtronic St Jude Medical None Biotronik Boston Scientific None Hugh Calkins, MD None Bard EP Boston Scientific † Medtronic † Atricure Bard EP Biosense Webster Boston Scientific Medtronic Reliant None Ablation Frontiers Atricure Bard EP Biosense Webster Boston Scientific Cyberheart CryoCor Medtronic ProRhythm Sanofis Aventis None Riccardo Cappato, MD Bard EP † Biosense † Boston Scientific † ELA Medical † St Jude Medical † Biosense † Boston Scientific † ELA Medical † St Jude Medical † Biosense † Boston Scientific † ELA Medical † St Jude Medical † Medtronic † Boston Scientific † Cameron Health † Bard EP † Biosense † Boston Scientific † ELA Medical † St Jude Medical † None Shih-Ann Chen, MD Boston Scientific † St Jude Medical † None Bard EP Biosense Webster St Jude Medical None None None Harry J.G. Crijns, MD Medtronic † Boston Scientific Medtronic St Jude Medical Astra Zeneca Biosence MEDA Sanofi Aventis St Jude Medical None Astra Zeneca Biosense Webster MEDA Sanofi Aventis None Ralph Damiano, MD Atricure † Boston Scientific Medical CV None Cryocath Edwards Lifesciences None Atricure † Medtronic † Medical CV None D. Wyn Davies, MD None None None Medtronic † ProRhythm Ablation Frontiers CryoCath St Jude Medical Medtronic † (Salary) David Haines, MD Bard EP Boston Scientific Cardiofocus ProRhythm None None nContact Bard EP Toray nContact (Intellectual Property Right) Michel Haissaguerre, MD Johnson & Johnson † Bard EP † None None None Johnson & Johnson † Bard † Johnson & Johnson † (Royalties) Bard EP † (Royalties) Yoshiko Iesaka, MD None None None None None None Warren M. Jackman, MD None None Atricure † Biosense Webster † Cardiofocus † ProRhythm † Stereotaxis † None Biosense Webster † Stereotaxis † ProRhythm † Cardiofocus † Atricure † CardioFocus † Pierre Jais, MD None None Bard EP Biosense Webster Philips EP Medical St Jude Medical † SORIN None Biosense Webster Philips EP Medical St Jude Medical † SORIN None Hans Kottkamp, MD None None Biosense Webster † St Jude Medical † None Biosense Webster St Jude Medical † None Karl Heinz Kuck, MD None None None Biosense Webster Stereotaxis † Biosense Webster St Jude Medical None Bruce Lindsay, MD None Boston Scientific † Medtronic † None None Boston Scientific † (terminated in May 2006) Stereotaxis (terminated in May 2006) None Francis Marchlinski, MD Biosense Webster † Boston Scientific † Medtronic † St Jude Medical † Biosense Webster † Boston Scientific † Medtronic † St Jude Medical † Biosense Webster Boston Scientific Medtronic St Jude Medical None Biosense Webster GE Healthcare None Patrick McCarthy, MD None None Atricure Medical CV † Boston Scientific † Medical CV † Medtronic † None J. Lluis Mont, MD Atricure Boston Scientific Johnson & Johnson Medtronic St Jude Medical None Boston Scientific Medtronic St Jude Medical None Boston Scientific Johnson & Johnson Medtronic St Jude Medical None Fred Morady, MD None None Biosense Webster Boston Scientific Medtronic Reliant St Jude Medical Ablation Frontiers † None Ablation Frontiers † (Intellectual Property Right) Koonlawee Nademanee, MD Biosense Webster † Medtronic † None Biosense Webster Boston Scientific Medtronic St Jude Medical None Biosense Webster St Jude Medical Biosense Webster † (Royalties) Andrea Natale, MD Biosense Webster † Boston Scientific Medtronic † St Jude Medical † None Biosense Webster Boston Scientific GEE Medtronic St Jude Medical Signalife None None None Douglas Packer, MD Biosense † Boston Scientific CardioFocus † CryoCath † ESI † St Jude Medical † Siemens † Symphony Medical † Transurgical † None Biosense † St Jude Medical † Bard EP Boston Scientific † CardioFocus † CryoCor Hansen Medical IRM † Medtronic Reliant Pharma St Jude Medical † Siemens † Symphony Medical † Transurgical † ESI † Carlo Pappone, MD None None None None Biosense Webster St Jude Medical Stereotaxis None Erik Prystowsky, MD Boston Scientific † Medtronic † St Jude Medical † Sanofi-Aventis † Cardionet † Stereotaxis † Bard † Biosense Webster Medtronic † Sanofi-Aventis † Stereotaxis † None Antonio Raviele, MD None None Biosense Webster None Biosense Webster Medtronic SQDM None Jeremy Ruskin, MD None Boston Scientific † Medtronic † St Jude Medical † Boston Scientific St Jude Medical Cameron Health † CardioOptics InnerPulse † Astellas † AstraZeneca † Biosense Webster † Cardiofocus CV Therapeutics † Cryocath Medtronic † Pfizer † Sanofis Aventis † Stereotaxis † None Richard Shemin, MD None None None None St Jude Medical † None A relationship is considered to be “modest” if it is less than “significant” under the preceding definition. † Significant. A relationship is considered to be “significant” if (1) the person receives $10,000 or more during any 12–month period or 5% or more of the person{\textquoteright}s gross income; or (2) the person owns 5% or more of the voting stock or share of the entity or owns $10,000 or more of the fair market value of the entity. Peer-Review Disclosures Reviewer (Organization) Research Grants Fellowship Support Speakers{\textquoteright} Bureau/Honoraria Ownership Interest Consultant/Advisory Board Other Carina Blomstrom-Lundqvist, MD (EHRA) None None None None None None Charles Bridges, MD (STS) None None None None Bayer None Christopher Fellows, MD (ACC) Boston Scientific St. Jude Medical None Boston Scientific St. Jude Medical None Boston Scientific St. Jude Medical None A. Marc Gillinov, MD (STS) Medtronic † None None AtriCure † AtriCure Boston Scientific Edwards Lifesciences † Medtronic St. Jude Medical Kapp Surgical Richard Hauer, MD (ECAS) None None None None None None Gerhard Hindriks, MD (EHRA) None None Biotronik None Biosense Webster Biotronik St. Jude Medical Bard EP Biosense Webster Jose Jalife, MD (HRS) None None None None None None Jonathan Kalman, MD (HRS) Medtronic † St Jude Medical † Biosense Webster Johnson & Johnson Medtronic † St Jude Medical † Biosense Webster Johnson & Johnson Medtronic † St Jude Medical † Medtronic † St Jude Medical † Peter Kowey, MD (ACC) None None None None None None Prof. Samuel Levy, MD (ECAS) None None None None None None William Maisel, MD (AHA) None None None None U.S. FDA None James Maloney, MD (HRS) None None Boston Scientific Medtronic Phillips EP Medical Reliant Pharmaceuticals St. Jude Medical None Boston Scientific Medtronic Philips EP Medical Reliant Pharmaceuticals St. Jude Medical None John M. Miller, MD (HRS) None None None None Biosense-Webster Boston Scientific Medtronic St. Jude Medical Stereotaxis Boston Scientific † Medtronic † St. Jude Medical † Jeffrey Olgin, MD (AHA) St. Jude Medical † None Boston Scientific † Medtronic † St. Jude Medical † None None Boston Scientific † Medtronic † St. Jude Medical † Richard Page, MD (ACC/AHA/HRS) Proctor and Gamble None None None Berlage Sanofi Aventis John Locke Trust Julian Perez-Villacastin, MD (EHRA) None None None None Boston Scientific Cordis Medtronic St. Jude Medical None Martin Schalij, MD (EHRA) None None None None None None Richard Schilling (ECAS) None None None None Biosense Webster Medtronic St. Jude Medical Biosense † Boston Scientific † Mel Scheinman, MD (AHA) None None Boston Scientific None None None Claudio D. Schuger, MD (ACC) Biosense Boston Scientific Medtronic None Boston Scientific None None None Gordon Tomaselli, MD (AHA/HRS) None None None None None None Cindy Tracy, MD (ACC) None None None None None None Al Waldo, MD (ACC) Reliant † Biosense Webster Biotronik ChanTest CryoCor Daiichi GlaxoSmithKline Reliant Pharmaceuticals Sanofi-Aventis St. Jude Medical A relationship is considered to be “modest” if it is less than “significant” under the preceding definition. † Significant. A relationship is considered to be “significant” if (1) the person receives $10,000 or more during any 12–month period or 5% or more of the person{\textquoteright}s gross income; or (2) the person owns 5% or more of the voting stock or share of the entity or owns $10,000 or more of the fair market value of the entity. ",

year = "2007",

month = jun,

doi = "10.1016/j.hrthm.2007.04.005",

language = "English (US)",

volume = "4",

pages = "816--861",

journal = "Heart rhythm",

issn = "1547-5271",

publisher = "Elsevier",

number = "6",

}

Calkins, H, Brugada, J, Packer, DL, Cappato, R, Chen, SA, Crijns, HJG, Damiano, RJ, Davies, DW, Haines, DE, Haissaguerre, M, Iesaka, Y, Jackman, W, Jais, P, Kottkamp, H, Kuck, KH, Lindsay, BD, Marchlinski, FE, McCarthy, PM, Mont, JL, Morady, F, Nademanee, K, Natale, A, Pappone, C, Prystowsky, E, Raviele, A, Ruskin, JN & Shemin, RJ 2007, 'HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Personnel, Policy, Procedures and Follow-Up. A report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA)', Heart rhythm, vol. 4, no. 6, pp. 816-861. https://doi.org/10.1016/j.hrthm.2007.04.005

HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Personnel, Policy, Procedures and Follow-Up. A report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA). / Calkins, Hugh; Brugada, Josep; Packer, Douglas L. et al.
In: Heart rhythm, Vol. 4, No. 6, 06.2007, p. 816-861.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation

T2 - Recommendations for Personnel, Policy, Procedures and Follow-Up. A report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA)

AU - Calkins, Hugh

AU - Brugada, Josep

AU - Packer, Douglas L.

AU - Cappato, Riccardo

AU - Chen, Shih Ann

AU - Crijns, Harry J G

AU - Damiano, Ralph J.

AU - Davies, D. Wyn

AU - Haines, David E.

AU - Haissaguerre, Michel

AU - Iesaka, Yoshito

AU - Jackman, Warren

AU - Jais, Pierre

AU - Kottkamp, Hans

AU - Kuck, Karl Heinz

AU - Lindsay, Bruce D.

AU - Marchlinski, Francis E.

AU - McCarthy, Patrick M.

AU - Mont, J. Lluis

AU - Morady, Fred

AU - Nademanee, Koonlawee

AU - Natale, Andrea

AU - Pappone, Carlo

AU - Prystowsky, Eric

AU - Raviele, Antonio

AU - Ruskin, Jeremy N.

AU - Shemin, Richard J.

N1 - Funding Information: Author Disclosures Task Force Members Research Grants Fellowship Support Speakers’ Bureau/Honoraria Ownership Interest Consultant/Advisory Board Other Josep Brugada, MD None Boston Scientific Boston Scientific Medtronic St Jude Medical None Biotronik Boston Scientific None Hugh Calkins, MD None Bard EP Boston Scientific † Medtronic † Atricure Bard EP Biosense Webster Boston Scientific Medtronic Reliant None Ablation Frontiers Atricure Bard EP Biosense Webster Boston Scientific Cyberheart CryoCor Medtronic ProRhythm Sanofis Aventis None Riccardo Cappato, MD Bard EP † Biosense † Boston Scientific † ELA Medical † St Jude Medical † Biosense † Boston Scientific † ELA Medical † St Jude Medical † Biosense † Boston Scientific † ELA Medical † St Jude Medical † Medtronic † Boston Scientific † Cameron Health † Bard EP † Biosense † Boston Scientific † ELA Medical † St Jude Medical † None Shih-Ann Chen, MD Boston Scientific † St Jude Medical † None Bard EP Biosense Webster St Jude Medical None None None Harry J.G. Crijns, MD Medtronic † Boston Scientific Medtronic St Jude Medical Astra Zeneca Biosence MEDA Sanofi Aventis St Jude Medical None Astra Zeneca Biosense Webster MEDA Sanofi Aventis None Ralph Damiano, MD Atricure † Boston Scientific Medical CV None Cryocath Edwards Lifesciences None Atricure † Medtronic † Medical CV None D. Wyn Davies, MD None None None Medtronic † ProRhythm Ablation Frontiers CryoCath St Jude Medical Medtronic † (Salary) David Haines, MD Bard EP Boston Scientific Cardiofocus ProRhythm None None nContact Bard EP Toray nContact (Intellectual Property Right) Michel Haissaguerre, MD Johnson & Johnson † Bard EP † None None None Johnson & Johnson † Bard † Johnson & Johnson † (Royalties) Bard EP † (Royalties) Yoshiko Iesaka, MD None None None None None None Warren M. Jackman, MD None None Atricure † Biosense Webster † Cardiofocus † ProRhythm † Stereotaxis † None Biosense Webster † Stereotaxis † ProRhythm † Cardiofocus † Atricure † CardioFocus † Pierre Jais, MD None None Bard EP Biosense Webster Philips EP Medical St Jude Medical † SORIN None Biosense Webster Philips EP Medical St Jude Medical † SORIN None Hans Kottkamp, MD None None Biosense Webster † St Jude Medical † None Biosense Webster St Jude Medical † None Karl Heinz Kuck, MD None None None Biosense Webster Stereotaxis † Biosense Webster St Jude Medical None Bruce Lindsay, MD None Boston Scientific † Medtronic † None None Boston Scientific † (terminated in May 2006) Stereotaxis (terminated in May 2006) None Francis Marchlinski, MD Biosense Webster † Boston Scientific † Medtronic † St Jude Medical † Biosense Webster † Boston Scientific † Medtronic † St Jude Medical † Biosense Webster Boston Scientific Medtronic St Jude Medical None Biosense Webster GE Healthcare None Patrick McCarthy, MD None None Atricure Medical CV † Boston Scientific † Medical CV † Medtronic † None J. Lluis Mont, MD Atricure Boston Scientific Johnson & Johnson Medtronic St Jude Medical None Boston Scientific Medtronic St Jude Medical None Boston Scientific Johnson & Johnson Medtronic St Jude Medical None Fred Morady, MD None None Biosense Webster Boston Scientific Medtronic Reliant St Jude Medical Ablation Frontiers † None Ablation Frontiers † (Intellectual Property Right) Koonlawee Nademanee, MD Biosense Webster † Medtronic † None Biosense Webster Boston Scientific Medtronic St Jude Medical None Biosense Webster St Jude Medical Biosense Webster † (Royalties) Andrea Natale, MD Biosense Webster † Boston Scientific Medtronic † St Jude Medical † None Biosense Webster Boston Scientific GEE Medtronic St Jude Medical Signalife None None None Douglas Packer, MD Biosense † Boston Scientific CardioFocus † CryoCath † ESI † St Jude Medical † Siemens † Symphony Medical † Transurgical † None Biosense † St Jude Medical † Bard EP Boston Scientific † CardioFocus † CryoCor Hansen Medical IRM † Medtronic Reliant Pharma St Jude Medical † Siemens † Symphony Medical † Transurgical † ESI † Carlo Pappone, MD None None None None Biosense Webster St Jude Medical Stereotaxis None Erik Prystowsky, MD Boston Scientific † Medtronic † St Jude Medical † Sanofi-Aventis † Cardionet † Stereotaxis † Bard † Biosense Webster Medtronic † Sanofi-Aventis † Stereotaxis † None Antonio Raviele, MD None None Biosense Webster None Biosense Webster Medtronic SQDM None Jeremy Ruskin, MD None Boston Scientific † Medtronic † St Jude Medical † Boston Scientific St Jude Medical Cameron Health † CardioOptics InnerPulse † Astellas † AstraZeneca † Biosense Webster † Cardiofocus CV Therapeutics † Cryocath Medtronic † Pfizer † Sanofis Aventis † Stereotaxis † None Richard Shemin, MD None None None None St Jude Medical † None A relationship is considered to be “modest” if it is less than “significant” under the preceding definition. † Significant. A relationship is considered to be “significant” if (1) the person receives $10,000 or more during any 12–month period or 5% or more of the person’s gross income; or (2) the person owns 5% or more of the voting stock or share of the entity or owns $10,000 or more of the fair market value of the entity. Peer-Review Disclosures Reviewer (Organization) Research Grants Fellowship Support Speakers’ Bureau/Honoraria Ownership Interest Consultant/Advisory Board Other Carina Blomstrom-Lundqvist, MD (EHRA) None None None None None None Charles Bridges, MD (STS) None None None None Bayer None Christopher Fellows, MD (ACC) Boston Scientific St. Jude Medical None Boston Scientific St. Jude Medical None Boston Scientific St. Jude Medical None A. Marc Gillinov, MD (STS) Medtronic † None None AtriCure † AtriCure Boston Scientific Edwards Lifesciences † Medtronic St. Jude Medical Kapp Surgical Richard Hauer, MD (ECAS) None None None None None None Gerhard Hindriks, MD (EHRA) None None Biotronik None Biosense Webster Biotronik St. Jude Medical Bard EP Biosense Webster Jose Jalife, MD (HRS) None None None None None None Jonathan Kalman, MD (HRS) Medtronic † St Jude Medical † Biosense Webster Johnson & Johnson Medtronic † St Jude Medical † Biosense Webster Johnson & Johnson Medtronic † St Jude Medical † Medtronic † St Jude Medical † Peter Kowey, MD (ACC) None None None None None None Prof. Samuel Levy, MD (ECAS) None None None None None None William Maisel, MD (AHA) None None None None U.S. FDA None James Maloney, MD (HRS) None None Boston Scientific Medtronic Phillips EP Medical Reliant Pharmaceuticals St. Jude Medical None Boston Scientific Medtronic Philips EP Medical Reliant Pharmaceuticals St. Jude Medical None John M. Miller, MD (HRS) None None None None Biosense-Webster Boston Scientific Medtronic St. Jude Medical Stereotaxis Boston Scientific † Medtronic † St. Jude Medical † Jeffrey Olgin, MD (AHA) St. Jude Medical † None Boston Scientific † Medtronic † St. Jude Medical † None None Boston Scientific † Medtronic † St. Jude Medical † Richard Page, MD (ACC/AHA/HRS) Proctor and Gamble None None None Berlage Sanofi Aventis John Locke Trust Julian Perez-Villacastin, MD (EHRA) None None None None Boston Scientific Cordis Medtronic St. Jude Medical None Martin Schalij, MD (EHRA) None None None None None None Richard Schilling (ECAS) None None None None Biosense Webster Medtronic St. Jude Medical Biosense † Boston Scientific † Mel Scheinman, MD (AHA) None None Boston Scientific None None None Claudio D. Schuger, MD (ACC) Biosense Boston Scientific Medtronic None Boston Scientific None None None Gordon Tomaselli, MD (AHA/HRS) None None None None None None Cindy Tracy, MD (ACC) None None None None None None Al Waldo, MD (ACC) Reliant † Biosense Webster Biotronik ChanTest CryoCor Daiichi GlaxoSmithKline Reliant Pharmaceuticals Sanofi-Aventis St. Jude Medical A relationship is considered to be “modest” if it is less than “significant” under the preceding definition. † Significant. A relationship is considered to be “significant” if (1) the person receives $10,000 or more during any 12–month period or 5% or more of the person’s gross income; or (2) the person owns 5% or more of the voting stock or share of the entity or owns $10,000 or more of the fair market value of the entity.

PY - 2007/6

Y1 - 2007/6

UR - http://www.scopus.com/inward/record.url?scp=34249814933&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249814933&partnerID=8YFLogxK

U2 - 10.1016/j.hrthm.2007.04.005

DO - 10.1016/j.hrthm.2007.04.005

M3 - Article

C2 - 17556213

AN - SCOPUS:34249814933

SN - 1547-5271

VL - 4

SP - 816

EP - 861

JO - Heart rhythm

JF - Heart rhythm

IS - 6

ER -

Calkins H, Brugada J, Packer DL, Cappato R, Chen SA, Crijns HJG et al. HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Personnel, Policy, Procedures and Follow-Up. A report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA). Heart rhythm. 2007 Jun;4(6):816-861. doi: 10.1016/j.hrthm.2007.04.005

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this